Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today that the Company has enrolled its first patient in a pivotal Phase III European/Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III European/Canadian psoriasis trial (ESSENCE trial) will be performed at ...
Cape Town, South Africa (ots/PRNewswire) - - First Rimonabant Trial with HbA1c as a Primary Endpoint Sanofi-aventis announced today that new data on rimonabant, its first-in-class cannabinoid type 1 (CB1) receptor blocker, showed that patients with type 2 diabetes not currently treated with anti-diabetic ...
Vancouver, Canada (ots/PRNewswire) - Perceptronix Medical Inc. ("Perceptronix") announced today that it has opened its first sputum induction facility at MDS Metro Laboratory Services' Victoria Drive Patient Service Centre in Vancouver. This facility will be the first centre to offer sputum induction for Perceptronix's ClearSign(TM) Sputum Test ("ClearSign(TM)"). ClearSign(TM) is a simple, non-invasive, early ...
Paris (ots/PRNewswire) - - Photographers From Across Europe Invited to Participate in Contest to Fight Stigma and Discrimination of HIV/AIDS Patients. Bristol-Myers Squibb announced today - World AIDS Day - the launch of the fourth edition of the One Vision European photography competition, an initiative that is literally helping to change the image of HIV and AIDS across Europe. "People are living longer ...
New York (ots/PRNewswire) - - Broad Access Program for Patients with Limited Available Treatment Options Pfizer announced today that it plans to establish a multi-national Expanded Access Program (EAP) to make the investigational CCR5 antagonist maraviroc, currently in ongoing phase 3 clinical ...
Edmonton, Canada, November 28 (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) today announced that its lead immunosuppressive drug, ISA247 is positioned to enter Phase II/ III human clinical trials in uveitis by its partner Lux Biosciences, following interactions with the Food and Drug Administration and ...
Pain Management Research Institute
Sydney, Australia, November 28 (ots/PRNewswire) - - Results Offer Hope to Patients With Excruciating Chronic Pain Findings from a new study published today in the journal Neurology demonstrate that the oral medication pregabalin is significantly effective in relieving central neuropathic (nerve) pain and improves pain-related sleep disturbance and anxiety in patients with spinal cord injury. Conducted by ...
Paris, November 22 (ots/PRNewswire) - - New Hope for CML and Ph+ ALL Patients who Face Resistance or Intolerance to Current Therapies For Non-US Journalists Only Today, the European Commission approved SPRYCEL(TM) (dasatinib, formerly known as BMS-354825) for the treatment of adults with chronic, ...
Edmonton, Alberta, November 21 (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) today announced the Company has received a Notice of Allowance from the United States Patent and Trademark Office based on U.S. Patent Application Serial No. 10/845,747 for TAFA93, including both composition of matter and methods of use claims. This is the first patent to be issued in ...
Swiftwater, Pennsylvania. and Lyon, France, November 20 (ots/PRNewswire) - - New Pre-Pandemic Vaccine Will Provide Additional Level of Preparedness sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY; EURONEXT: SAN) has signed a contract with the Office of Public Health and ...
Shire Pharmaceuticals Group Plc
Basingstoke, England and San Diego, California, November 20 (ots/PRNewswire) - - Further Data Support the Contribution of FOSRENOL(R) (Lanthanum Carbonate) to the Overall Renal Health of the ESRD Patient While Reducing Mean Phosphate Levels to Within Guideline Targets New data presented on Friday 17th ...
Alliance for Better Bone Health
Paris, November 17 (ots/PRNewswire) - - Actonel Almost Halves the Risk of Breaking a Hip When Compared to Alendronate in the First Year of Treatment - For Non-US Journalists Only Data published today from a retrospective study of over 33,000 postmenopausal women showed that among patients newly ...
Macclesfield, England, November 17 (ots/PRNewswire) - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Published in the Lancet Oncology Report That Patients are More Likely to Live Cancer Free for Longer if Tamoxifen is Replaced With ARIMIDEXT(TM) According to data published today in the Lancet ...
Edmonton, Canada, November 16 (ots/PRNewswire) - - Transplant Data Presented at the American Society of Nephrology Conference Isotechnika Inc. today announced results from initial data for its Phase IIb kidney transplant trial of the Company's lead immunosuppressive drug, ISA247. To date, 133 patients have been enrolled in the trial. Based on an early ...
Basel, Switzerland, November 16 (ots/PRNewswire) - - New England Journal of Medicine Article Shows no Additional Cardiac Benefit From Increasing Haemoglobin to Levels Outside Current Recommendations The long awaited results of CREATE (i), a landmark trial that investigated a key question in nephrology, were published today. CREATE set out to see if there was ...
Alderley Park, England, November 16 (ots/PRNewswire) - - First Patient Enrolled in Phase III International Randomised, Double-Blind, Placebo-Controlled Study of Vandetanib for Non-Small Cell Lung Cancer (NSCLC) After Failure of EGFR TKI Therapy AstraZeneca today announced the start of enrolment into a new Phase III study of the novel once-daily oral ...
Las Vegas, November 15 (ots/PRNewswire) - - New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that patients with elevated intraocular pressure (IOP) - along with other ...
Edmonton, Canada, November 15 (ots/PRNewswire) - Isotechnika Inc. will announce initial data from its Phase IIb kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Thursday, November 16th at 8:00 a.m. ET/6:00 a.m. MT. Dr. Randall Yatscoff, Isotechnika's President & CEO, will present the initial data via web cast commencing at 9:00 a.m. ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 15 (ots/PRNewswire) - - New Sub-analyses Provide Insight into Treatment Benefits New data from the combined RESIST studies (RESIST-1 and RESIST-2) show that Aptivus(R) (tipranavir), used with ritonavir (tipranavir/r) as part of combination antiretroviral therapy, continued to ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Also Found Compatible with Other Medicines Used by HIV/AIDS Patients A review of 17 drug-drug interaction studies involving the investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC125 was presented today as a plenary oral paper at the Eighth International Congress on Drug Therapy in HIV Infection (HIV8) in Glasgow, Scotland. The data ...
Glasgow, Scotland, November 14 (ots/PRNewswire) - - Data Presented at HIV 8 Conference - New studies on the use of PREZISTA(TM), an investigational anti-HIV medication, suggest that it can be co-administered with many common medications taken by people with HIV, including other antiretrovirals, proton pump inhibitors, H2 blockers and selective serotonin reuptake inhibitors. According to current HIV ...
Glasgow, Scotland, November 13 (ots/PRNewswire) - - Patients Treated With Boosted Invirase 500 Were Significantly Less Likely to Develop Elevated Lipids Than Boosted Lopinavir Promising head to head results presented today indicate that the boosted protease inhibitor (PI/r) Invirase 500/r appears to ...
Stafford, England, November 10 (ots/PRNewswire) - To meet the volume demand from the NHS for its unique system MedifyRemote(tm), Medify Solutions (Pink Sheets - MDFY.PK) today announced that its link into the NHS now requires a PSTN link upgrade to accommodate NHS customer base user login. Whilst causing a slight delay, this activity has now been categorised by NHS BT management as a national "hot issue". BT ...
Ingelheim, Germany, November 10 (ots/PRNewswire) - - Millions of People Worldwide Living With RLS to Benefit as Treatment Becomes Globally Available Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has approved pramipexole, a non-ergot dopamine agonist, for the ...
Paris, November 9 (ots/PRNewswire) - - Data to be Presented at Upcoming American College of Rheumatology Annual Meeting Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of abatacept in adult patients with moderate to severe rheumatoid arthritis (RA) who have ...
Burcon NutraScience Corporation
Vancouver, Canada, November 7 (ots/PRNewswire) - Burcon NutraScience Corporation (TSX-V: BU) announced today that it has recently entered into a number of additional three-way material transfer agreements ("MTA's") enabling the provision of samples of Burcon's proteins, Puratein(R) and Supertein(TM), to third parties for testing while protecting certain intellectual property interests of all of the parties involved. The recipients of the protein samples include ...
Calgary, Canada, November 3 (ots/PRNewswire) - - Canadian Biotechnology Company's Intellectual Property Position Strengthened by Decision TSX symbol: SBS SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical ...
Toronto, Canada, November 2 (ots/PRNewswire) - EMIS, the UK's leading provider of IT systems to the primary care market is preparing to make the MedifyRemote product available across its UK customer base. Approximately 55% of all doctors in the UK currently use EMIS software each day. EMIS has been instrumental, through the NHS pilots, making sure the product not only meets customers needs but also the ...
Basel, Switzerland (ots/PRNewswire) - Seventy percent of European patients battling lung cancer had never regarded the disease as a threat prior to learning of their condition, according to results from a new pan-European public and patient survey announced on the eve of Lung Cancer Awareness Month. This ignorance about lung cancer is also indicative of a chronic ...